论文部分内容阅读
目的:探讨热疗联合放化疗对宫颈癌患者免疫能力的影响。方法:抽签将2013年1月-2015年6月于我院住院的82例宫颈癌患者随机均分为两组。对照组(41例)进行放化疗,观察组(41例)在对照组的基础上配合热疗。通过比较两组患者治疗前后T淋巴细胞亚群及NK细胞数目,进而评估两组患者的免疫功能;比较两组患者的临床疗效。结果:治疗前两组患者T淋巴细胞亚群及NK细胞数目比较差异无统计学意义(P>0.05);治疗后观察组各T淋巴细胞亚群——CD4+(27.54±5.08)%、CD8+(29.64±5.31)%、CD4+/CD8+(1.82±1.11)%及NK细胞数目(19.73±4.18)%较治疗前的(22.16±4.32)%、(24.56±4.13)%、(0.84±1.03)%、(14.32±3.67)%及对照组的(24.64±5.07)%、(26.82±5.14)%、(1.27±1.12)%、(16.54±4.13)%显著较高,差异有统计学意义(P<0.05)。治疗后观察组患者总有效率为92.68%,较对照组的70.73%显著较高,差异有统计学意义(P<0.05)。结论:在治疗宫颈癌患者时,与单独使用放化疗相比,热疗联合放化疗可明显提高患者的免疫能力,进而提高临床疗效,改善患者的生存质量。
Objective: To investigate the effect of hyperthermia combined with radiotherapy and chemotherapy on the immune function of cervical cancer patients. Methods: Lottery 82 cases of cervical cancer hospitalized in our hospital from January 2013 to June 2015 were randomly divided into two groups. The control group (41 cases) was treated with radiotherapy and chemotherapy. The observation group (41 cases) was treated with hyperthermia on the basis of the control group. By comparing the two groups of patients before and after treatment of T lymphocyte subsets and NK cell number, and then evaluate the immune function of two groups of patients; the clinical efficacy of the two groups were compared. Results: There was no significant difference in the numbers of T lymphocyte subsets and NK cells between the two groups before treatment (P> 0.05). After treatment, the levels of T lymphocyte subsets - CD4 + (27.54 ± 5.08)%, CD8 + (22.6 ± 4.32)%, (24.56 ± 4.13)%, (0.84 ± 1.03)%, (29.64 ± 5.31)%, CD4 + / CD8 + (1.82 ± 1.11)% and the number of NK cells (19.73 ± 4.18) (14.32 ± 3.67)% and (24.64 ± 5.07)% and (26.82 ± 5.14)% and (1.27 ± 1.12)% and (16.54 ± 4.13)% in the control group, respectively, with significant difference ). After treatment, the total effective rate of the observation group was 92.68%, which was significantly higher than that of the control group (70.73%), the difference was statistically significant (P <0.05). Conclusion: In the treatment of patients with cervical cancer, compared with radiotherapy and chemotherapy alone, combined with radiotherapy and chemotherapy can significantly improve the immune capacity of patients, thereby improving the clinical efficacy and improve the quality of life of patients.